Advanced search
Start date
Betweenand


Transplantation of genetically modified cardiac fibroblasts to induce angiogenesis and vasculogenesis in ischemic myocardium

Full text
Author(s):
Giovana Aparecida Gonçalves
Total Authors: 1
Document type: Doctoral Thesis
Press: São Paulo.
Institution: Universidade de São Paulo (USP). Faculdade de Medicina (FM/SBD)
Defense date:
Examining board members:
Jose Eduardo Krieger; Fabio Fernandes; Kleber Gomes Franchini; Antonio Ricardo de Toledo Gagliardi; Carlos Frederico Martins Menck
Advisor: Jose Eduardo Krieger
Abstract

The effect of modified cardiac fibroblasts (CF) expressing VEGF (vascular endothelial growth factor) and/or IGF-1 (insulin-like growth factor) associated to fibrin biopolymer to induce angiogenesis, vasculogenesis and improve cardiac function in ischemic cardiac tissue was tested. The direct injection of 106 CF genetically modified to express the reporter gene LACZ (AdRSVLACZ) indicated transgene expression up to 45 days. First, all groups were treated and 7 days later the animals were submitted to a 45 min cardiac ischemic injury. Twenty one days later VEGF protein and capillary density increased only in groups that received VEGF the groups: (VEGF protein: 1209.6±11.4 vs. VEHICLE: 123.1±5.2, Cell: 104.2±7.4 and Null: 73.2±2.4 positive cells/field, p< 0.01 and capillary: 543.8 ± 52.1 vs. 349.2 ± 0.9, 288± 19.0 and 245 ± 2.6 capillaries/mm2, p< 0.01). Merged image of immunoassaying for endothelial and smooth muscle cells specific markers, were significantly greater in VEGF group suggesting maturation of newly formed vessels (45±3 vs. 10±2, 8±1 and 16±3, p<0.001) and myocardial scar area was reduced in VEGF vs. VEHICLE (3.0 ± 1.3% vs. 8.0 ± 0.8%, p< 0.05). To test the therapeutic efficacy of this treatment, a second study was performed with groups: VEHICLE= control, POLYMER= fibrin biopolymer, CELL, NULL, IGF-1, VEGF and IGF-1+VEGF. Treatments were performed 24 hs following ligation of the descending coronary artery. After 4 weeks, VEGF and IGF-1 protein increased in IGF-1, VEGF and IGF-1+VEGF groups, p<0.0001. We observed only in VEGF groups an increase in capillary number and vascular density and reduction in myocardial collagen area (35,12 ± 7,05 vs. 31,28 ± 5,03 vs. 30,07 ± 6,21 vs. 25,89 ± 2,92 vs. 15,43 ± 2,02* vs. 16,07 ± 1,83%*, *p<0,05, to groups VEHICLE, POLYMER, CELL, NULL, IGF-1, VEGF, IGF-1+VEGF, respectively). The morphological and functional basal cardiac indices remained unchanged in all groups, however, under pharmacologic stress using phenilephrine, the VEGF groups displayed significant improvement in cardiac work and stroke volume and a reduction in end diastolic pressure. Taken together, these results indicated that cardiac fibroblasts expressing VEGF alone or in combination with IGF-1 can induce agiogenesis and vasculogenesis in ischemic myocardium decreasing myocardial scar area and improving cardiac performance following coronary ligation. (AU)